CTKBCytek Biosciences Inc. Common Stock
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lig…
Industry Peers
Medical Devices| Headline | Source | Time |
|---|---|---|
Older | ||
 Cytek (CTKB) Q2 2026 Earnings Call Transcript U.S. revenue surged 18% while EMEA declined 8% amid geopolitical pressures. | ||
 Cytek Biosciences, Inc. Q2 2026 Earnings Call Summary Moby summary of Cytek Biosciences, Inc.'s Q2 2026 earnings call | ||
Cytek Biosciences Inc (CTKB) (Q2 2026) Earnings Call Highlights: Revenue Up 6% to $48. ... Cytek Biosciences Inc (CTKB) delivers solid Q2 2026 results with 6% revenue growth, launches the industry-first Borealis 60-color system, and raises full-year guidance despite EMEA softness. | ||
 Cytek Biosciences Q2 Earnings Call Highlights Cytek Biosciences (NASDAQ:CTKB) reported second-quarter 2026 revenue growth of 6% year over year, supported by double-digit gains in the United States and China, while continued weakness in Europe and parts of Asia-Pacific limited overall growth. Revenue for the quarter ended June 30 was $48.1 mill | ||
 Cytek Biosciences, Inc. (CTKB) Reports Q2 Loss, Tops Revenue Estimates Cytek Biosciences (CTKB) delivered earnings and revenue surprises of -150.00% and +1.66%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Kyntra Bio (KYNB) Expected to Beat Earnings Estimates: Should You Buy? Kyntra Bio (KYNB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. | ||
 Analysts Estimate Cytek Biosciences, Inc. (CTKB) to Report a Decline in Earnings: What to Look Out for Cytek Biosciences (CTKB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. | ||
 CSBR vs. CTKB: Which Life Sciences Stock Has Better Long-Term Upside? Champions Oncology and Cytek Biosciences have different growth drivers and valuations, but which life sciences stock offers better long-term upside? Let's dive in. | ||